How many insider trades does FilingIQ track for FEMY?

FilingIQ tracks 47 Form 4 insider transactions for FEMY (FEMASYS INC), covering filings from Jun 18, 2021 onwards. 10 of those were filed in the last 90 days.

Are FEMY insiders net buyers or net sellers?

Across the full Form 4 history for FEMY, 7 transactions (15%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does FEMY insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is FEMY in?

FEMASYS INC (FEMY) is classified in the Healthcare sector, specifically Medical Instruments & Supplies, with a current market capitalisation of $32.45M.

FEMY insider trading

NasdaqCM Healthcare

FEMASYS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

Last 90 days

Buys / sells

15% / 0%

Market cap

$32.45M

About FEMASYS INC

Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.

Company website: www.femasys.com

FEMY insider activity at a glance

FilingIQ has scored 47 insider transactions for FEMY since Jun 18, 2021. The most recent filing in our index is dated Mar 30, 2026.

Across the full history, 7 open-market purchases and 0 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on FEMY insider trades is 46.9/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live FEMY trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Frequently asked

How many insider trades does FilingIQ track for FEMY?: FilingIQ tracks 47 Form 4 insider transactions for FEMY (FEMASYS INC), covering filings from Jun 18, 2021 onwards. 10 of those were filed in the last 90 days.
Are FEMY insiders net buyers or net sellers?: Across the full Form 4 history for FEMY, 7 transactions (15%) were open-market purchases and 0 (0%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does FEMY insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is FEMY in?: FEMASYS INC (FEMY) is classified in the Healthcare sector, specifically Medical Instruments & Supplies, with a current market capitalisation of $32.45M.

Methodology & sources

Every FEMY insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.